InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-25.9%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Mowry Anna, Chief Financial Officer. Director active across 1 company, notably Nautilus Biotechnology, Inc.. In total, 6 reports have been published. Breakdown: 6 buys · 0 sell. Total volume traded: €406k. Activity tracked since 12 August 2021. The latest transaction was filed on 19 August 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
17,500 shares@ US$2.29829.8% of flowCommon StockSEC:0001808805-22-000095:0
Ideal exit: 16 May 2023 (T+270)
5,500 shares@ US$2.74990.0058% mcap3.9% of flowCommon StockSEC:0001808805-22-000075:0
Ideal exit: 24 Mar 2023 (T+270)
15,000 shares@ US$4.57550.025% mcap16.7% of flowCommon StockSEC:0001808805-21-000023:0
Ideal exit: 21 Aug 2022 (T+270)
15,000 shares@ US$4.575515.0% of flowCommon StockSEC:0001808805-21-000023
Ideal exit: 21 Aug 2022 (T+270)
17,500 shares@ US$7.7128.3% of flowCommon StockSEC:0001808805-21-000012
Ideal exit: 9 May 2022 (T+270)
17,500 shares@ US$7.710.047% mcap31.4% of flowCommon StockSEC:0001808805-21-000012:0
Ideal exit: 9 May 2022 (T+270)
6 of 6 declarations
About Mowry Anna
Anna Mowry is Chief Financial Officer and Treasurer at Nautilus Biotechnology, Inc. She oversees the financial management of the company, including financial planning and reporting. Her role is essential for ensuring the financial health and growth of the company.
